Balancing co-stimulation and inhibition with BTLA and HVEM - PubMed (original) (raw)

The miRNA and PD-1/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer.

Yadav R, Khatkar R, Yap KC, Kang CY, Lyu J, Singh RK, Mandal S, Mohanta A, Lam HY, Okina E, Kumar RR, Uttam V, Sharma U, Jain M, Prakash H, Tuli HS, Kumar AP, Jain A. Yadav R, et al. Cell Death Discov. 2024 Sep 29;10(1):414. doi: 10.1038/s41420-024-02182-1. Cell Death Discov. 2024. PMID: 39343796 Free PMC article. Review.

The BTLA-HVEM axis restricts CAR T cell efficacy in cancer.

Guruprasad P, Carturan A, Zhang Y, Cho JH, Kumashie KG, Patel RP, Kim KH, Lee JS, Lee Y, Kim JH, Chung J, Joshi A, Cohen I, Shestov M, Ghilardi G, Harris J, Pajarillo R, Angelos M, Lee YG, Liu S, Rodriguez J, Wang M, Ballard HJ, Gupta A, Ugwuanyi OH, Hong SJA, Bochi-Layec AC, Sauter CT, Chen L, Paruzzo L, Kammerman S, Shestova O, Liu D, Vella LA, Schuster SJ, Svoboda J, Porazzi P, Ruella M. Guruprasad P, et al. Nat Immunol. 2024 Jun;25(6):1020-1032. doi: 10.1038/s41590-024-01847-4. Epub 2024 Jun 3. Nat Immunol. 2024. PMID: 38831106